Paul Matteis
Stock Analyst at Stifel
(2.93)
# 2,662
Out of 5,022 analysts
114
Total ratings
44.74%
Success rate
0.04%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $441 → $495 | $469.36 | +5.46% | 15 | Oct 6, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $43 → $67 | $71.37 | -6.12% | 6 | Oct 6, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Buy | $27 | $15.62 | +72.86% | 1 | Oct 6, 2025 | |
| PEPG PepGen | Maintains: Buy | $9 → $12 | $4.58 | +162.01% | 3 | Sep 25, 2025 | |
| QURE uniQure | Maintains: Buy | $30 → $65 | $58.96 | +10.24% | 2 | Sep 24, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $494 → $455 | $412.22 | +10.38% | 19 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $166 → $174 | $137.23 | +26.79% | 9 | Jul 31, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $66 → $36 | $15.45 | +133.01% | 4 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $105.20 | -10.65% | 2 | May 29, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $1.80 | +11.11% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $29.88 | +7.10% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $13.32 | +140.24% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $6.84 | +60.82% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.99 | +33.78% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $5.62 | +77.94% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $33.20 | +80.72% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $31.94 | +12.71% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $52.47 | +65.81% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $24.88 | +40.68% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $20.36 | +3.14% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $11.67 | +148.50% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $145.31 | +97.51% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.50 | +135.29% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.01 | +199.25% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $360 → $50 | $3.68 | +1,258.70% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $11.54 | +177.30% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.33 | +1,058.80% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $14.37 | -2.57% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $7.89 | +711.15% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $110.64 | +207.30% | 1 | Dec 21, 2016 |
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Buy
Price Target: $441 → $495
Current: $469.36
Upside: +5.46%
Ionis Pharmaceuticals
Oct 6, 2025
Maintains: Hold
Price Target: $43 → $67
Current: $71.37
Upside: -6.12%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Buy
Price Target: $27
Current: $15.62
Upside: +72.86%
PepGen
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $4.58
Upside: +162.01%
uniQure
Sep 24, 2025
Maintains: Buy
Price Target: $30 → $65
Current: $58.96
Upside: +10.24%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Hold
Price Target: $494 → $455
Current: $412.22
Upside: +10.38%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Buy
Price Target: $166 → $174
Current: $137.23
Upside: +26.79%
Dyne Therapeutics
Jul 31, 2025
Maintains: Buy
Price Target: $66 → $36
Current: $15.45
Upside: +133.01%
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $105.20
Upside: -10.65%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $1.80
Upside: +11.11%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $29.88
Upside: +7.10%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $13.32
Upside: +140.24%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $6.84
Upside: +60.82%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.99
Upside: +33.78%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $5.62
Upside: +77.94%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $33.20
Upside: +80.72%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $31.94
Upside: +12.71%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $52.47
Upside: +65.81%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $24.88
Upside: +40.68%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $20.36
Upside: +3.14%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $11.67
Upside: +148.50%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $145.31
Upside: +97.51%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $8.50
Upside: +135.29%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $4.01
Upside: +199.25%
Jun 23, 2022
Downgrades: Hold
Price Target: $360 → $50
Current: $3.68
Upside: +1,258.70%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $11.54
Upside: +177.30%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.33
Upside: +1,058.80%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $14.37
Upside: -2.57%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $7.89
Upside: +711.15%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $110.64
Upside: +207.30%